Global Peptide Oligonucleotide Conjugate (POC) Market Growth 2024-2030

Publication ID:

LPI10249891

Publication Date:

October 14, 2024

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Manufacturing (Chemicals) [2]

Chemicals [3]

Description:

Peptide Oligonucleotide Conjugate (POC) refer to complexes formed by connecting peptides and oligonucleotides through chemical or biological methods. This type of conjugate combines the characteristics of peptides and oligonucleotides and has a variety of potential biological functions and applications. POC can achieve targeted recognition and binding through the peptide part, and achieve functions such as gene regulation or nucleic acid interference through the oligonucleotide part. It usually has good biocompatibility and is suitable for use in the biomedical field.
The global Peptide Oligonucleotide Conjugate (POC) market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淧eptide Oligonucleotide Conjugate (POC) Industry Forecast鈥� looks at past sales and reviews total world Peptide Oligonucleotide Conjugate (POC) sales in 2023, providing a comprehensive analysis by region and market sector of projected Peptide Oligonucleotide Conjugate (POC) sales for 2024 through 2030. With Peptide Oligonucleotide Conjugate (POC) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide Oligonucleotide Conjugate (POC) industry.
This Insight Report provides a comprehensive analysis of the global Peptide Oligonucleotide Conjugate (POC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Peptide Oligonucleotide Conjugate (POC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Peptide Oligonucleotide Conjugate (POC) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide Oligonucleotide Conjugate (POC) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide Oligonucleotide Conjugate (POC).
United States market for Peptide Oligonucleotide Conjugate (POC) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Peptide Oligonucleotide Conjugate (POC) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Peptide Oligonucleotide Conjugate (POC) is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Peptide Oligonucleotide Conjugate (POC) players cover Creative Biogene, CPC, BOCSCI Inc., WuXi TIDES, LifeTein, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide Oligonucleotide Conjugate (POC) market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Single Chain
Double Chain
Segmentation by Application:
Diagnostic Reagents
Drug Development
Gene Therapy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Creative Biogene
CPC
BOCSCI Inc.
WuXi TIDES
LifeTein
Bio-Synthesis
Ajinomoto
SBS Genetech
Medtide Inc
Kaneka Corporation(Eurogentec)
Key Questions Addressed in this Report
What is the 10-year outlook for the global Peptide Oligonucleotide Conjugate (POC) market?
What factors are driving Peptide Oligonucleotide Conjugate (POC) market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Peptide Oligonucleotide Conjugate (POC) market opportunities vary by end market size?
How does Peptide Oligonucleotide Conjugate (POC) break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Peptide Oligonucleotide Conjugate (POC) Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Peptide Oligonucleotide Conjugate (POC) by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Peptide Oligonucleotide Conjugate (POC) by Country/Region, 2019, 2023 & 2030
2.2 Peptide Oligonucleotide Conjugate (POC) Segment by Type
2.2.1 Single Chain
2.2.2 Double Chain
2.3 Peptide Oligonucleotide Conjugate (POC) Sales by Type
2.3.1 Global Peptide Oligonucleotide Conjugate (POC) Sales Market Share by Type (2019-2024)
2.3.2 Global Peptide Oligonucleotide Conjugate (POC) Revenue and Market Share by Type (2019-2024)
2.3.3 Global Peptide Oligonucleotide Conjugate (POC) Sale Price by Type (2019-2024)
2.4 Peptide Oligonucleotide Conjugate (POC) Segment by Application
2.4.1 Diagnostic Reagents
2.4.2 Drug Development
2.4.3 Gene Therapy
2.4.4 Other
2.5 Peptide Oligonucleotide Conjugate (POC) Sales by Application
2.5.1 Global Peptide Oligonucleotide Conjugate (POC) Sale Market Share by Application (2019-2024)
2.5.2 Global Peptide Oligonucleotide Conjugate (POC) Revenue and Market Share by Application (2019-2024)
2.5.3 Global Peptide Oligonucleotide Conjugate (POC) Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Peptide Oligonucleotide Conjugate (POC) Breakdown Data by Company
3.1.1 Global Peptide Oligonucleotide Conjugate (POC) Annual Sales by Company (2019-2024)
3.1.2 Global Peptide Oligonucleotide Conjugate (POC) Sales Market Share by Company (2019-2024)
3.2 Global Peptide Oligonucleotide Conjugate (POC) Annual Revenue by Company (2019-2024)
3.2.1 Global Peptide Oligonucleotide Conjugate (POC) Revenue by Company (2019-2024)
3.2.2 Global Peptide Oligonucleotide Conjugate (POC) Revenue Market Share by Company (2019-2024)
3.3 Global Peptide Oligonucleotide Conjugate (POC) Sale Price by Company
3.4 Key Manufacturers Peptide Oligonucleotide Conjugate (POC) Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Peptide Oligonucleotide Conjugate (POC) Product Location Distribution
3.4.2 Players Peptide Oligonucleotide Conjugate (POC) Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Peptide Oligonucleotide Conjugate (POC) by Geographic Region
4.1 World Historic Peptide Oligonucleotide Conjugate (POC) Market Size by Geographic Region (2019-2024)
4.1.1 Global Peptide Oligonucleotide Conjugate (POC) Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Peptide Oligonucleotide Conjugate (POC) Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Peptide Oligonucleotide Conjugate (POC) Market Size by Country/Region (2019-2024)
4.2.1 Global Peptide Oligonucleotide Conjugate (POC) Annual Sales by Country/Region (2019-2024)
4.2.2 Global Peptide Oligonucleotide Conjugate (POC) Annual Revenue by Country/Region (2019-2024)
4.3 Americas Peptide Oligonucleotide Conjugate (POC) Sales Growth
4.4 APAC Peptide Oligonucleotide Conjugate (POC) Sales Growth
4.5 Europe Peptide Oligonucleotide Conjugate (POC) Sales Growth
4.6 Middle East & Africa Peptide Oligonucleotide Conjugate (POC) Sales Growth
5 Americas
5.1 Americas Peptide Oligonucleotide Conjugate (POC) Sales by Country
5.1.1 Americas Peptide Oligonucleotide Conjugate (POC) Sales by Country (2019-2024)
5.1.2 Americas Peptide Oligonucleotide Conjugate (POC) Revenue by Country (2019-2024)
5.2 Americas Peptide Oligonucleotide Conjugate (POC) Sales by Type (2019-2024)
5.3 Americas Peptide Oligonucleotide Conjugate (POC) Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide Oligonucleotide Conjugate (POC) Sales by Region
6.1.1 APAC Peptide Oligonucleotide Conjugate (POC) Sales by Region (2019-2024)
6.1.2 APAC Peptide Oligonucleotide Conjugate (POC) Revenue by Region (2019-2024)
6.2 APAC Peptide Oligonucleotide Conjugate (POC) Sales by Type (2019-2024)
6.3 APAC Peptide Oligonucleotide Conjugate (POC) Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Peptide Oligonucleotide Conjugate (POC) by Country
7.1.1 Europe Peptide Oligonucleotide Conjugate (POC) Sales by Country (2019-2024)
7.1.2 Europe Peptide Oligonucleotide Conjugate (POC) Revenue by Country (2019-2024)
7.2 Europe Peptide Oligonucleotide Conjugate (POC) Sales by Type (2019-2024)
7.3 Europe Peptide Oligonucleotide Conjugate (POC) Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Peptide Oligonucleotide Conjugate (POC) by Country
8.1.1 Middle East & Africa Peptide Oligonucleotide Conjugate (POC) Sales by Country (2019-2024)
8.1.2 Middle East & Africa Peptide Oligonucleotide Conjugate (POC) Revenue by Country (2019-2024)
8.2 Middle East & Africa Peptide Oligonucleotide Conjugate (POC) Sales by Type (2019-2024)
8.3 Middle East & Africa Peptide Oligonucleotide Conjugate (POC) Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Peptide Oligonucleotide Conjugate (POC)
10.3 Manufacturing Process Analysis of Peptide Oligonucleotide Conjugate (POC)
10.4 Industry Chain Structure of Peptide Oligonucleotide Conjugate (POC)
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Peptide Oligonucleotide Conjugate (POC) Distributors
11.3 Peptide Oligonucleotide Conjugate (POC) Customer
12 World Forecast Review for Peptide Oligonucleotide Conjugate (POC) by Geographic Region
12.1 Global Peptide Oligonucleotide Conjugate (POC) Market Size Forecast by Region
12.1.1 Global Peptide Oligonucleotide Conjugate (POC) Forecast by Region (2025-2030)
12.1.2 Global Peptide Oligonucleotide Conjugate (POC) Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Peptide Oligonucleotide Conjugate (POC) Forecast by Type (2025-2030)
12.7 Global Peptide Oligonucleotide Conjugate (POC) Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Creative Biogene
13.1.1 Creative Biogene Company Information
13.1.2 Creative Biogene Peptide Oligonucleotide Conjugate (POC) Product Portfolios and Specifications
13.1.3 Creative Biogene Peptide Oligonucleotide Conjugate (POC) Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Creative Biogene Main Business Overview
13.1.5 Creative Biogene Latest Developments
13.2 CPC
13.2.1 CPC Company Information
13.2.2 CPC Peptide Oligonucleotide Conjugate (POC) Product Portfolios and Specifications
13.2.3 CPC Peptide Oligonucleotide Conjugate (POC) Sales, Revenue, Price and Gross Margin (2019-2024)
13.2.4 CPC Main Business Overview
13.2.5 CPC Latest Developments
13.3 BOCSCI Inc.
13.3.1 BOCSCI Inc. Company Information
13.3.2 BOCSCI Inc. Peptide Oligonucleotide Conjugate (POC) Product Portfolios and Specifications
13.3.3 BOCSCI Inc. Peptide Oligonucleotide Conjugate (POC) Sales, Revenue, Price and Gross Margin (2019-2024)
13.3.4 BOCSCI Inc. Main Business Overview
13.3.5 BOCSCI Inc. Latest Developments
13.4 WuXi TIDES
13.4.1 WuXi TIDES Company Information
13.4.2 WuXi TIDES Peptide Oligonucleotide Conjugate (POC) Product Portfolios and Specifications
13.4.3 WuXi TIDES Peptide Oligonucleotide Conjugate (POC) Sales, Revenue, Price and Gross Margin (2019-2024)
13.4.4 WuXi TIDES Main Business Overview
13.4.5 WuXi TIDES Latest Developments
13.5 LifeTein
13.5.1 LifeTein Company Information
13.5.2 LifeTein Peptide Oligonucleotide Conjugate (POC) Product Portfolios and Specifications
13.5.3 LifeTein Peptide Oligonucleotide Conjugate (POC) Sales, Revenue, Price and Gross Margin (2019-2024)
13.5.4 LifeTein Main Business Overview
13.5.5 LifeTein Latest Developments
13.6 Bio-Synthesis
13.6.1 Bio-Synthesis Company Information
13.6.2 Bio-Synthesis Peptide Oligonucleotide Conjugate (POC) Product Portfolios and Specifications
13.6.3 Bio-Synthesis Peptide Oligonucleotide Conjugate (POC) Sales, Revenue, Price and Gross Margin (2019-2024)
13.6.4 Bio-Synthesis Main Business Overview
13.6.5 Bio-Synthesis Latest Developments
13.7 Ajinomoto
13.7.1 Ajinomoto Company Information
13.7.2 Ajinomoto Peptide Oligonucleotide Conjugate (POC) Product Portfolios and Specifications
13.7.3 Ajinomoto Peptide Oligonucleotide Conjugate (POC) Sales, Revenue, Price and Gross Margin (2019-2024)
13.7.4 Ajinomoto Main Business Overview
13.7.5 Ajinomoto Latest Developments
13.8 SBS Genetech
13.8.1 SBS Genetech Company Information
13.8.2 SBS Genetech Peptide Oligonucleotide Conjugate (POC) Product Portfolios and Specifications
13.8.3 SBS Genetech Peptide Oligonucleotide Conjugate (POC) Sales, Revenue, Price and Gross Margin (2019-2024)
13.8.4 SBS Genetech Main Business Overview
13.8.5 SBS Genetech Latest Developments
13.9 Medtide Inc
13.9.1 Medtide Inc Company Information
13.9.2 Medtide Inc Peptide Oligonucleotide Conjugate (POC) Product Portfolios and Specifications
13.9.3 Medtide Inc Peptide Oligonucleotide Conjugate (POC) Sales, Revenue, Price and Gross Margin (2019-2024)
13.9.4 Medtide Inc Main Business Overview
13.9.5 Medtide Inc Latest Developments
13.10 Kaneka Corporation(Eurogentec)
13.10.1 Kaneka Corporation(Eurogentec) Company Information
13.10.2 Kaneka Corporation(Eurogentec) Peptide Oligonucleotide Conjugate (POC) Product Portfolios and Specifications
13.10.3 Kaneka Corporation(Eurogentec) Peptide Oligonucleotide Conjugate (POC) Sales, Revenue, Price and Gross Margin (2019-2024)
13.10.4 Kaneka Corporation(Eurogentec) Main Business Overview
13.10.5 Kaneka Corporation(Eurogentec) Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂